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ABSTRACT
Osteoarthritis is a chronic degenerative disorder of the joint and
represents one of the most common diseases worldwide. Its
prevalence and severity are increasing owing to aging of the
population, but treatment options remain largely limited to painkillers
and anti-inflammatory drugs, which only provide symptomatic relief.
In the late stages of the disease, surgical interventions are often
necessary to partially restore joint function. Although the focus of
osteoarthritis research has been originally on the articular cartilage,
novel findings are now pointing to osteoarthritis as a disease of the
whole joint, in which failure of different joint components can occur.
In this Review, we summarize recent progress in the field, including
data from novel ‘omics’ technologies and from a number of preclinical
and clinical trials. We describe different in vitro and in vivo systems
that can be used to study molecules, pathways and cells that are
involved in osteoarthritis. We illustrate that a comprehensive and
multisystem approach is necessary to understand the complexity and
heterogeneity of the disease and to better guide the development of
novel therapeutic strategies for osteoarthritis.
KEY WORDS: Osteoarthritis, Cartilage, Bone, Animal models
Introduction
Osteoarthritis (OA) is a chronic and progressive joint disorder
characterized by structural damage to one or more joints that can be
recognized on X-ray imaging (Fig. 1). With worldwide estimates
that over 10% of the population above 60 years is affected by OA,
the impact of this health problem is still underestimated (Hunter et
al., 2014). The course of the disease is highly variable between
affected individuals: single or multiple joints can be involved and
symptoms can vary from mild to severe joint pain and stiffness,
often leading to loss of joint function and permanent disability. The
prevalence of OA increases with age. Genetic as well as acquired
factors, which include joint trauma and life-style-associated risk
factors (such as obesity and excessive joint use in occupational or
leisurely activities) can contribute to the onset and progression of
the disease (Bijlsma et al., 2011; Hunter and Felson, 2006; Lane,
2007). The socioeconomic impact of OA is high and, because aging
and obesity are increasing in the population, costs for OA
management will also likely increase in the future (Lawrence et al.,
2008; Hunter et al., 2014). Current treatment options for OA are
limited. In addition to physiotherapy, regular exercise and weight
loss, pharmacological interventions are restricted to symptomatic
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relief with local (intra-articular) injections of corticosteroids and/or
systemic administration of analgesics and non-steroidal anti-
inflammatory drugs (NSAIDs) (Berenbaum, 2008; Bijlsma et al.,
2011). In the most severe cases, osteotomy (a surgical intervention
aimed at changing the load pattern in the joint by altering leg
alignment) or joint prosthesis (replacing the joint with an artificial
device to take over its function and reduce pain) seem to be the only
options to partially restore joint functionality and improve quality of
life.
Joints are complex organs in which different tissues functionally
cooperate to allow movement between the bones of the skeleton,
while at the same time limiting the degree and the axes of
movement. In the joint, a thin layer of articular cartilage caps the
hard and calcified bones. This specialized tissue is rich in
extracellular matrix components that attract abundant water
molecules, which absorb and translate to the bones the compressive
loading forces that are applied to the joint during movements. The
joint cavity is further lined by the synovium, a thin connective tissue
that produces the lubricating synovial fluid. Finally, ligaments and
capsules provide further strength to the joint. A classical view
considers OA primarily as a disease of the articular cartilage.
Fibrillations and ulcerations, loss of extracellular matrix and cell
death occur in this tissue. Damage in the articular cartilage is
typically characterized by fissures in its superficial layer that
gradually extend into the deeper layers and finally lead to severe loss
of cartilage structure and volume. This will then result in secondary
changes to the underlying (subchondral) bone and to other tissues of
the joint. However, recent observations suggest that OA should be
approached as a failure of the entire joint organ and that early
disease-related changes can be detected both in the cartilage and in
the subchondral bone (Brandt et al., 2008; Brandt et al., 2006; Lories
and Luyten, 2011). OA can result from the dysregulation of a
complex set of biomechanical and biochemical interactions between
multiple structures, which can disrupt the normal homeostasis of the
joint (Loeser et al., 2012; Lories, 2011). For example, progressive
cartilage loss, subchondral bone remodelling, formation of
osteophytes (bony outgrowths) at the joint margins and synovial
inflammation (synovitis) are among the processes that characterize
OA pathophysiology and which will eventually contribute to
increasing joint pain and functional impairment. Although
inflammation can take part in the osteoarthritic processes, it is not
the dominant driving force of this disease. Other joint diseases, such
as rheumatoid arthritis, are driven by inflammation in the first place,
whereas damage to cartilage and bone is a secondary phenomenon.
The tissues of the joint work together in order to maintain joint
homeostasis. Failure in even a single component of the joint can
compromise its functionality and progressively lead to the failure of
the whole organ (Fig. 1) (Lories and Luyten, 2011).
Further understanding of the molecular and cellular basis of OA
is fundamental to guide the identification of new therapeutic targets
and the development of specific strategies and interventions.
Therefore, a whole range of in vitro and in vivo systems are
currently used to study different aspects of joint physiology in health
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and disease. Here, we review some of the targets that have emerged
from the study of joint function and from genetic association studies.
We also discuss recent progress in OA research, with special
attention to discoveries made by transcriptomic, proteomic and
epigenomic approaches. This provides a platform to discuss how
current technologies might help the development of new therapeutic
approaches in OA and to identify some of the challenges related to
the translation of basic OA research into the clinic.
Searching for targets and therapies in OA
The goal of OA research is to search for new therapeutic strategies
that could prevent, reduce or stop the progression of the disease or,
alternatively, resolve the existing damage to the joint. Unfortunately,
the development of such interventions is complex and challenging
owing to the multifactorial complexity of the disease. Until now,
combined efforts from academia and industry have failed to bring
disease-modifying anti-OA drugs (DMOADs), with convincing
efficacy and reliable safety properties, into daily clinical practice
(Bijlsma et al., 2011; Martel-Pelletier et al., 2012). The reason for
this failure is partially due to the need for a more comprehensive
knowledge of the major pathophysiological factors that contribute
to the disease process and progression. However, as described in the
following sections, the study of joint physiology and recent
advancements in genetic and ‘omics’ technologies have helped
identify important players and potential therapeutic targets in OA.
As exemplified in Fig. 2, in some cases (which will be described in
more detail below), basic knowledge of the processes of joint
development and homeostasis has driven subsequent steps in
experimental research and revealed key factors associated with OA.
Learning from joint physiology: emerging targets and drugs
Fundamental knowledge derived from the study of joint
development and homeostasis has driven the identification of
promising targets for OA treatment. Enzymes, cytokines and growth
factors that regulate cartilage differentiation and destruction,
subchondral bone remodelling and synovial inflammation are
among the most appealing targets, because all those processes play
a crucial role in OA.
Biochemical and molecular studies have identified a series of
enzymes that play an active role in the breakdown of the
extracellular matrix of the articular cartilage during OA. These
include matrix metalloproteinases (MMPs) and a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS)
enzymes (Cawston and Young, 2010; Stanton et al., 2005; Troeberg
and Nagase, 2012). Although seemingly effective in in vitro and in
vivo preclinical settings, chemical inhibition of such enzymes, which
should counteract cartilage loss, has been challenged by safety
issues in human clinical trials (Catterall and Cawston, 2003;
Clutterbuck et al., 2009).
Growth factors and (stem) cell-based approaches have received a
lot of attention for their ability to enhance extracellular matrix
synthesis and thereby preserve cartilage or stimulate its repair in OA
(Fortier et al., 2011). For example, the bone morphogenetic protein
7 (BMP-7), also known as osteogenic protein 1 (OP-1), is a growth
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Fig. 1. X-ray radiographic images showing structural alterations of the
joints that are most commonly affected by OA. (A) Normal and (A′)
severely affected joint of the hip, characterized by joint space narrowing
(arrow) and osteophyte (bony outgrowth) formation (arrowheads). (B) Normal
and (B′) severely affected joint of the knee, showing alterations in the medial
compartment, with almost complete disappearance of the joint space (arrow)
and lateral involvement. (C) Normal and (C′) severely affected joint of the
hand. The panel shows the distal interphalangeal joint with disappearance of
the joint space and small osteophyte formation (arrowheads).
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BMP signalling: GDF5 
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Fig. 2. Different steps in the discovery of two factors that play a
key role in joint physiology and pathophysiology. Growth and
differentiation factor-5 (GDF5) and frizzled-related protein (FRZB)
were both originally identified from a chondrogenic extract of adult
articular cartilage. In joint development, GDF5 is specifically
expressed in the joint interzone, where the future joint will form.
Mutations in the GDF5 gene result in severe skeletal malformations,
with joint fusions in both mouse and human. In humans, single
nucleotide polymorphisms (SNPs) within the GDF5 gene have been
associated with OA susceptibility. In mouse mutants, more severe
OA is observed. FRZB function is linked to chondrocyte proliferation
during development. SNPs in the human FRZB gene have been
associated with hip OA. Induced models of OA in mice show
increased severity of disease in the absence of the Frzb gene.
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factor that stimulates cartilage and bone formation during embryonic
development and postnatal growth (Boon et al., 2011; Chubinskaya
et al., 2007), and has shown good promise in preclinical models of
arthritis (Badlani et al., 2008; Badlani et al., 2009; Hayashi et al.,
2008; Hayashi et al., 2010; Hurtig et al., 2009; Sekiya et al., 2009;
Takahashi et al., 2011). Fibroblast growth factor 18 (FGF-18) is
another growth factor that plays a central role in skeletal growth and
development (Liu et al., 2002; Ohbayashi et al., 2002), and acts as
a ligand for the FGF-receptor 3 (FGFR3) pathway (Davidson et al.,
2005). In particular, FGF-18 exerts strong anabolic effects on
chondrocytes – the unique cell type found in the articular cartilage
that synthesizes the characteristic extracellular matrix of the tissue
(Ellman et al., 2013; Ellsworth et al., 2002; Moore et al., 2005) –
and its capacity to stimulate cartilage repair was demonstrated in a
rat meniscal tear model of OA (Moore et al., 2005). In addition to
its direct effects on cartilage growth, FGF-18 might also stimulate
the BMP signalling by repressing the BMP antagonist Noggin
(Reinhold et al., 2004). Currently, both OP-1 and FGF-18 are being
tested in OA clinical trials (Hunter et al., 2010; Lohmander et al.,
2014). Autologous chondrocyte transplantation has been
successfully implemented in the clinical practice for repairing
traumatic cartilage lesions (Harris et al., 2010; Minas, 2012), a
condition that can predispose to OA; however, this approach is
currently not suitable for the treatment of advanced OA-induced
cartilage damage because this is too diffuse to approach with current
surgical techniques or autologous chondrocyte transplantation
(Luyten and Vanlauwe, 2012).
Abnormal remodelling of the subchondral bone is also associated
with OA and usually leads to the production of a thicker but
mechanically less responsive tissue (Lories and Luyten, 2011).
Therefore, targeting subchondral bone metabolism in OA could also
be an approach for OA treatment. Until now, strontium ranelate is
the only drug reported to have an anti-bone-resorption (or
breakdown) effect and at the same time a positive effect on bone
formation (Bonnelye et al., 2008; Marie et al., 2011; Tat et al.,
2011). Previous studies also suggested an anabolic effect of this drug
on cartilage (Henrotin et al., 2001). The beneficial effects of
strontium ranelate have been confirmed in OA patients
(Alexandersen et al., 2011; Reginster et al., 2013) but, recently,
important safety issues related to the use of this agent (i.e. an
increased risk of acute coronary syndrome) have been raised
(EMEA, 2013). Nevertheless, a recent nationwide cohort study in
Denmark did not support an association between strontium ranelate
and acute coronary syndrome (Svanström et al., 2014), thus, the
safety aspects associated with this drug remain controversial.
Calcitonin, a hormone that regulates calcium homeostasis and
bone formation, is another molecule of interest that has been
successfully used for the treatment of osteoporosis (Binkley et al.,
2012). Osteoporosis is a common skeletal disease characterized by
low bone mass and abnormal bone architecture that increase the risk
of bone fracture. Drugs in osteoporosis treatment typically target the
breakdown of bone by osteoclasts, a process that is out of balance
in this disease. Although calcitonin demonstrated a protective effect
on joint damage in a rat preclinical model of OA (Nielsen et al.,
2011), it failed to prove therapeutic in a Phase III clinical trial
(Karsdal et al., 2014). Bisphosphonates, another class of drug that
targets bone breakdown by osteoclasts and is widely used for the
treatment of osteoporosis, have also been tested in OA but the results
remain controversial (Davis et al., 2013; Laslett et al., 2013).
Additionally, cathepsin K (a protease responsible for the degradation
of bone matrix by osteoclasts) is an interesting drug target because
it regulates both cartilage and subchondral bone homeostasis
(Connor et al., 2009; Dejica et al., 2012; Dejica et al., 2008; Hayami
et al., 2012; McDougall et al., 2010), but its role has not been fully
explored in OA. More recently, transforming growth factor-beta
[TGFβ; a pleiotropic growth factor that has been extensively studied
for its anabolic effects on cartilage (van der Kraan, 2014)] has been
considered for OA because of the important effects that this factor
elicits on the subchondral bone. Overexpression of TGFβ in
osteoblasts (the bone-forming cells) and in the subchondral bone
induces OA, whereas inhibition of its signalling pathway prevents
OA, suggesting that the inhibition of TGFβ might be a potential
treatment strategy for OA (Zhen et al., 2013).
Synovial inflammation is commonly seen in individuals with OA
and is characterized by the production and release of pro-
inflammatory cytokines and other inflammatory mediators. At least
some of these factors diffuse via the synovial fluid into the
superficial layer of the cartilage, where they activate the production
of catabolic factors by chondrocytes thereby leading to cartilage
destruction. IL-1β and TNFα are two of the major cytokines
involved in OA-associated synovial inflammation (Kapoor et al.,
2011). In light of this, the inhibition of the IL-1β and TNFα
pathways has been tested as a therapeutic strategy in OA. In the case
of IL-1β, several approaches have been explored to inhibit its
activity, including the block of the IL-1β converting enzyme (ICE),
the application of IL-1β receptor antagonists or of soluble receptors,
and the use of specific antibodies against this cytokine (Jotanovic et
al., 2012). Unfortunately, so far these strategies have failed to
demonstrate consistent clinical effects in both hand and knee OA
(Chevalier et al., 2009; Cohen et al., 2011; Shin et al., 2013; Yang
et al., 2008). Anti-TNFα drugs can successfully treat rheumatoid
arthritis. This has triggered interest in assessing these compounds in
OA, in particular in hand OA because this form often presents with
severe joint inflammation. However, in the past few years, results
from independent small clinical trials have questioned the feasibility
of this approach because of the lack of clear therapeutic effects for
OA patients (Chevalier et al., 2014; Güler-Yüksel et al., 2010;
Maksymowych et al., 2012; Verbruggen et al., 2012).
GFD5 and DOTL1: two promising targets suggested by genetic
studies
OA has a complex etiology to which genetic, acquired and
environmental factors contribute (Reynard and Loughlin, 2013). The
presence of a genetic component in OA is supported by a growing
number of sources, including epidemiological and linkage studies,
candidate gene approaches, and genome-wide association studies
(GWAS). However, all these approaches are complex and still present
some difficulties. Indeed, the discovery of genetic susceptibility
factors associated with OA has been hindered by the presence of
multiple phenotypical manifestations of the disease, which made the
definition and classification of patient phenotypes particularly
challenging and, thus, limited the power of genetic association
analyses (Kerkhof et al., 2011). Candidate gene approaches in OA
research have been debated because suggested associations were
rarely replicated in multiple population studies (Reynard and
Loughlin, 2013). Novel technologies, such as GWAS and meta-
analyses on large datasets and multiple cohorts, proved promising for
OA and succeeded in identifying regions with multiple candidate
genes, for instance a gene cluster on chromosome 7q22 that includes
COG5, HBP1, DUS4L, PRKAR2B and GPR22 (Evangelou et al.,
2014; Kerkhof et al., 2010; Rodriguez-Fontenla et al., 2014;
Styrkarsdottir et al., 2014; Zeggini et al., 2012). However, the role of
some of these genes in joint physiology still needs to be fully
explored. In this section, we illustrate some of the main challenges
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beyond genetic association studies, focusing in particular on two
potential targets that emerged from these approaches.
Growth and differentiation factor 5 [GDF5; also known as
cartilage derived morphogenic protein 1 (CDMP1)] is a member of
the BMP/TGFβ superfamily and was originally identified from a
chondrogenic extract of bovine healthy articular cartilage (Chang et
al., 1994) (Fig. 2). During joint development, this factor is
specifically expressed in the joint interzone [the region in which
future joints will form (Storm and Kingsley, 1996)], where it
stimulates proliferation and differentiation of chondrocytes. In
humans, loss-of-function mutations in GDF5 cause severe skeletal
phenotypes characterized by joint fusions (Polinkovsky et al., 1997;
Thomas et al., 1997; Thomas et al., 1996). A 5′ untranslated region
(UTR) C/T single-nucleotide polymorphism (SNP) (rs143383) has
been associated with susceptibility to OA in the Japanese and Han
Chinese population, with this variant resulting in lower levels of
GDF5 expression (Miyamoto et al., 2007). The association between
the rs143383 SNP and OA is one of a few that have been confirmed
in different ethnic groups and by meta-analysis (Evangelou et al.,
2009; Valdes and Spector, 2011). Because of the chondrogenic
properties of GDF5, it is not surprising that genetic variations
leading to decreased levels of its expression can affect cartilage
growth and contribute to OA. However, the role of GDF5 seems
much more complex and alterations of its function might also affect
other tissues of the joint. For example, GDF5 deficiency in mice
results in abnormal ligament laxity and could thereby contribute to
OA development by reducing joint stability (Daans et al., 2011). In
addition, GDF5 might also affect subchondral bone remodelling, as
suggested by the fact that reduced GDF5 levels are associated with
an abnormal structure of the collagen fibres of the bone (Daans et
al., 2011). GDF5 has not been used as a pharmaceutical target up
until now, but in principle it could be considered as a factor that
stimulates cartilage extracellular matrix synthesis and could
strengthen ligaments.
As highlighted above, GWAS studies in OA have been hampered
by the heterogeneity of disease phenotypes, which has also guided
the search for alternative measures of disease outcomes (disease
‘endpoints’) to be used for the identification of potential genetic
associations. An example of such an approach is represented by an
OA GWAS in which the hip joint space width was used as a
measure of cartilage thickness (Castaño Betancourt et al., 2012).
This study identified a genetic variant in the DOT1-like histone H3
methyltransferase (DOT1L) gene that was robustly associated with
increased joint space width and reduced risk for hip OA in
Caucasian populations. DOT1L is an evolutionarily conserved
enzyme and the only known H3K79 methyltransferase (Nguyen and
Zhang, 2011). Originally identified in yeast telomere silencing
(Singer et al., 1998), it functions as a positive mediator of gene
transcription and DNA repair, and as a regulator of the cell cycle
(Nguyen and Zhang, 2011). In cancer, oncogenic fusion proteins
caused by chromosomal rearrangements have been linked to
DOT1L-mediated leukemogenesis (Mueller et al., 2007). The
DOT1L association is attractive for directing future therapeutic
strategies in OA based on different considerations. First, DOT1L is
an enzyme and, thus, can be targeted by pharmacological agents
(Barry et al., 2010), with DOT1L inhibitors already being tested in
cancer clinical trials (Daigle et al., 2011; Deshpande et al., 2012).
Moreover, DOT1L was shown to interact with the Wnt signalling
cascade (Castaño Betancourt et al., 2012; Mahmoudi et al., 2010), a
molecular signalling pathway that plays essential roles in joint and
bone development and which has been extensively studied in the last
decade and proposed as a potential target in OA (Lories et al., 2013).
Unfortunately, direct targeting of Wnt signalling proteins has been
difficult because recombinant Wnts are difficult to obtain mainly
due to solubility issues; additionally, Wnt signalling has also been
associated with cancer, thereby raising concerns about intervening
within this pathway. These obstacles could be overcome by using
DOT1L as an alternative target. Finally, genetic variants in both the
DOT1L (Sovio et al., 2009) and other OA susceptibility genes
(Sanna et al., 2008) have also been associated with variations in
human height, further supporting the involvement of factors that
regulate bone growth in the disease.
Target discovery based on ‘omics’ technologies
Transcriptomics, proteomics and epigenomics respectively study and
map the RNAs, proteins and epigenomic modifications of different
cell types and tissues from human and model organisms. These
datasets can be compared between healthy and disease states to
better understand the mechanisms underlying a disease and to guide
the development of new therapeutic strategies, a principle that also
applies to OA. Transcriptomics has already been shown to be a
powerful tool to gain knowledge of the onset and progression of
OA. For instance, transcriptome profiles of cartilage from wild-type
mice and mice lacking ADAMTS5 (an aggrecan-destructive enzyme
associated with OA, as already mentioned above) with surgically
induced OA identified several genes (e.g. Ptgs2, Crlf1, Padi2 and
Col8a2) that might contribute to OA initiation and whose role seems
independent of ADAMTS5 activity (Bateman et al., 2013).
Previously, our group performed a microarray of transcripts obtained
from the articular cartilage and subchondral bone of wild-type and
Frzb-knockout (Frzb−/−) mice (Lodewyckx et al., 2012). Frizzled-
related protein (FRZB) is a secreted antagonist of the Wnt signalling
pathway (Wang et al., 1997) and was originally discovered in a
chondrogenic extract of articular cartilage and linked to chondrocyte
proliferation (Hoang et al., 1996) (Fig. 2). Polymorphisms in the
human FRZB gene were associated with hip OA in a Caucasian
population (Loughlin et al., 2004). Our observation that other Wnt
antagonists show compensatory upregulation in the absence of
FRZB in the knockout model supports the concept that the Wnt
signalling pathway is tightly regulated in the joint while also
emphasizing the molecular complexity of the Wnt signalling
pathway in the regulation of joint homeostasis (Lodewyckx et al.,
2012).
Gene or RNA expression levels cannot predict the exact amount
and the level of activity of proteins that are produced in a cell at a
given time, because these are both strongly influenced by processes
of alternative splicing, post-translational modifications and protein
degradation. Therefore, proteomics offers the possibility to describe
what might be truly happening in a tissue in terms of its protein
repertoire and content. Proteomic analyses performed on both in
vitro and ex vivo systems, including cultured chondrocytes,
osteoblasts, synoviocytes or cartilage explants, have already
contributed to the identification of potential drug targets. For
example, combined transcriptomic and proteomic analyses of
synovial fluids and membranes from OA patients showed elevated
levels of activation of the complement pathway, a series of proteins
that have effector functions in the innate immune system (Wang et
al., 2011). These data were confirmed by in vivo experiments with
mice deficient in complement component 5 (C5), C6 or the
complement regulatory protein CD59a (Wang et al., 2011). Absence
of complement components protected against OA development in
different induced mouse models of OA. In particular, absence of C5
reduced the amount and effects of inflammatory and tissue-
destructive molecules in the joint. Blocking of complement
REVIEW Disease Models & Mechanisms (2015) doi:10.1242/dmm.016881
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activation in the joint could therefore be considered a therapeutic
target and merits further attention.
Additionally, large-scale screening of proteomic datasets can be
used to search for potential OA-related biomarkers in body fluids
that are rich in protein content, such as blood plasma and serum,
urine and synovial fluid. The identification of reliable biomarkers
for OA would help optimize the diagnosis of the disease and
monitoring its progression.
Epigenetic changes are defined as heritable stable alterations in
the expression of a gene that occurs without modifications of its
DNA sequence. DNA methylation, histone modifications and RNA-
associated gene silencing [induced by small non-coding microRNAs
(miRNAs)] are the three basic mechanisms that play crucial roles in
epigenetic gene regulation, in both physiological and pathological
conditions. Epigenetic alterations can also influence the expression
of OA susceptibility genes. For example, DNA methylation was
shown to regulate the allelic expression imbalance of rs143383
(Reynard et al., 2011), an SNP of the GDF5 gene that is associated
with a higher risk of OA, as mentioned above. Epigenetic alterations
might also represent a feasible target for drug therapy. Indeed, intra-
articular injections of trichostatin A, a small molecule that inhibits
histone deacetylases (HDACs), decreased cartilage damage in a
surgically induced OA model in rabbits (Chen et al., 2010). In
addition, miRNAs seem to play an important role in OA, as
suggested by a study showing that the expression of miRNA-140,
which increases during normal chondrocytic differentiation of
mesenchymal stem cells, is reduced in human articular cartilage of
OA patients, likely in response to IL-1β (Miyaki et al., 2010), one
of the OA-associated cytokines. Until now, epigenetic approaches
in OA have focused primarily on the analysis of single genes.
However, with ‘omics’ technologies in continuous expansion, a
whole-genome epigenetic fingerprint analysis of OA tissues might
become feasible in the near future.
In vitro models of the joint
In vitro models are important tools to elucidate the molecular
mechanisms and pathways that are involved in joint physiology and
pathophysiology. These models include ex vivo tissue samples,
primary cell cultures and cell lines but also more complex setups
that allow the study of the interaction between different cells and
tissues within the joint. In this section, we will review pros and cons
of in vitro systems of the joint with a particular focus on cartilage
models.
In vitro models of the cartilage
The articular cartilage has a key structural and functional role in
joint physiology and disease; therefore, a high number of in vitro
models have been developed to study this specialized tissue in
normal and pathological conditions. In ex vivo tissue systems the
cartilage is isolated from the rest of the organism and can be tested
in experimentally controlled conditions to detect specific
pathological hallmarks via biochemical and immunohistochemical
techniques. Potential disadvantages of this approach include the
descriptive nature of the data collected limiting the mechanistic
insights that can be obtained, the fact that the tissue of interest is
isolated from potential systemic influences, and difficulties
associated with defining positive and negative controls, in particular
the ethical considerations when normal cartilage is required. More
functional studies can be performed using ex vivo tissue cultures.
For example, slices of human osteoarthritic cartilage or mice
femoral head caps can be kept in culture to allow the analysis of
their protein secretion profile in the presence or absence of specific
factors that can mimic an OA-associated environment (Liu-Bryan
and Terkeltaub, 2010; Ozaki et al., 2004). These models have
several drawbacks, such as a limited availability of tissue and high
inter-experimental variability. However, they have been useful to
elucidate the contribution of different tissue-destructive enzymes in
cartilage degradation, e.g. MMP-3 and MMP-13 (Liu-Bryan and
Terkeltaub, 2010). Tissue explants, but also cells cultured in
hydrogels, can be used to mimic the behaviour of the cells in an
extracellular-matrix-like environment in biomechanical loading
experiments, thereby assessing the effects of mechanical strain on
chondrocytes (Bryant et al., 2004; Quinn et al., 1998; Treppo et al.,
2000).
Primary articular chondrocytes isolated from animal or human
donor cartilage tissue can also be used as an in vitro model. The
main issue with this type of culture is that chondrocytes rapidly lose
their molecular signature when taken out of the joint environment
and quickly dedifferentiate (Abbott and Holtzer, 1966; Holtzer et al.,
1960). High-density pellet cultures or embedding of the cells in
agarose can be an option to maintain the chondrocyte phenotype in
culture at least to some extent (Häuselmann et al., 1994; Tew et al.,
2008). However, as discussed in more detail below, this feature of
primary cultures could also be an advantage, because
dedifferentiation and phenotypical changes are often associated with
OA. Clear disadvantages of primary cells include the difficulty to
obtain a sufficient number of cells, the diversity of cells within the
cultures as compared to other cell lines, and the fact that the cells
are not easy to transfect, thereby limiting the possibility to alter the
expression of target genes (via loss- or gain-of-function mutations)
to elucidate their role in OA. In addition, appropriate and reliable
control tissues are limited because healthy human articular
chondrocytes are hard to obtain because of ethical considerations,
whereas chondrocytes isolated from non-pathological subregions of
OA joints might already show signs of disease at the molecular
level, such as reduced collagen type II and aggrecan expression
(Squires et al., 2003). Indeed, articular chondrocytes have a very
specific molecular profile (for instance, they typically express type
II collagen) that clearly differs from the profile of chondrocytes
found in other postnatal cartilaginous tissues such as the epiphyseal,
nose and ear cartilages (Dell’Accio et al., 2001). However, under
pathological conditions, articular chondrocytes seem to lose their
phenotypical stability, they start to dedifferentiate or differentiate
towards hypertrophy, and can eventually undergo necrosis or
apoptosis (Lotz and Loeser, 2012). Cartilage hypertrophy is
characterized by a switch in the production of the extracellular
matrix proteins (from collagen type II to type X) and can be
accompanied by phenomena of matrix mineralization (Lefebvre and
Bhattaram, 2010; Lotz and Loeser, 2012). These processes normally
occur during cartilage development and growth but can be
deleterious for the articular cartilage in the adult. The molecular
mechanisms regulating the phenotypical changes associated with
OA are believed to recapitulate at least some of the differentiation
steps that take place during cartilage development. Therefore,
signalling pathways that are typically activated during joint
development, such as TGFβ, BMP, WNT and FGF have been
investigated in chondrocyte culture models of OA (Lories, 2011).
Interestingly, as reported previously in the text, a number of
potential OA susceptibility genes have emerged from the study of
these pathways (as extensively reviewed in Reynard and Loughlin,
2013).
The mechanisms and the molecular signatures that characterize
chondrocyte differentiation and hypertrophy can be also modelled
in immortalized clonal cell lines. In these lines, cells can be
21
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produced in large amounts and grown indefinitely, offering an ideal
tool to explore molecular and biochemical processes. For example,
the ATDC5 cell line, derived from mouse teratocarcinoma cells, is
a chondrogenic cell line that undergoes sequential stages of
differentiation analogous to the ones that are recognized during
cartilage development. Therefore, this cell line represents a well-
established model to study the factors and signalling pathways that
influence cell behaviour during the processes of chondrogenesis,
chondrocyte differentiation and terminal differentiation to
hypertrophy (Atsumi et al., 1990; Newton et al., 2012). Gain- or
loss-of-function mutations of specific genes can also be easily
induced by cell transfection: stable cell lines can be established
within a month of transfection. In addition, ATDC5 cells can be
cultured in monolayer, in three-dimensional (3D) micromasses/
pellets or in agarose beads. The use of 3D cultures is particularly
advantageous in experimental setups because a 3D matrix structure
of collagens and proteoglycans favours the expression of the normal
phenotype of the cartilage and the 3D environment also allows the
formation of cell-matrix interactions, which are essential during
chondrogenesis (Castaño Betancourt et al., 2012). These important
features are obviously not reproducible in monolayer cell cultures.
Recent studies on the role of hypoxia induced factor-2a (HIF2a) and
DOT1L (Castaño Betancourt et al., 2012; Saito et al., 2010) illustrate
the potential of such a standardized system: HIF2a was
demonstrated to stimulate chondrocyte hypertrophy and DOT1L
shown to be essential in early cartilage differentiation.
Other cell lines of interest include human articular cartilage
immortalized cell lines (Goldring et al., 1994), among which the C-
28/I2 line seems particularly valuable for the study of cartilage
physiology. In fact, this cell line expresses a high level of matrix-
associated molecules that are involved in both cartilage anabolic and
catabolic processes (Finger et al., 2003). Detailed analysis
demonstrated that human cartilage immortalized cell lines show
essential cartilage-specific features, but further investigations are
necessary to evaluate whether they can reliably substitute primary
chondrocyte cells (Finger et al., 2004; Finger et al., 2003). This
limitation also applies to other chondrocyte cells lines, including
ATDC5 cells.
Finally, stem cell lines are particularly attractive because of their
potential therapeutic use in regenerative medicine and have been
explored also for applications in OA. Controlled induction of
induced pluripotent stem cells (iPSCs) has been used as a tool to
reprogramme dermal cells in order to obtain large amounts of
cartilage-like tissue, which could be used for cartilage repair
(Hiramatsu et al., 2011). Mesenchymal stem cells are multipotent
stem cells that give rise to multiple connective tissue lineages,
including cartilage and bone. These cells have been isolated from
different human or animal tissues such as bone marrow, adipose
tissue and synovium. In vitro analyses and in vivo cell differentiation
assays using xeno-cell transfer in immunodeficient mice showed
that optimization of culture media and stimulation with growth
factors is necessary to obtain the desired cell differentiation in these
cells (De Bari et al., 2001; Eyckmans et al., 2012; Pittenger et al.,
1999). Current limitations to the use of stem cells for OA are
numerous and include challenges in defining optimal cell
populations in patient selection and in surgical methods required for
proper cell transfer (for an extensive discussion see Luyten and
Vanlauwe, 2012).
Other in vitro systems: the bone and the synovial tissues
Bone remodelling is an active and dynamic process that is finely
regulated by catabolic and anabolic reactions, through which bone
components are constantly broken down and built up. Dysregulation
of bone homeostasis can lead to several skeletal pathologies,
including OA, which is often associated with alterations in the
subchondral bone turnover (Karsdal et al., 2014). As described
above for the cartilage, several in vitro models can be applied to
study bone remodelling in OA and these include ex vivo tissues, cell
cultures and lines, and also more complex tissue culture systems that
allow the investigation of the interactions between bone and
cartilage cells. Several pre-osteoblastic and osteoblastic cell lines are
available and can be used to study the differentiation of bone-
forming cells (Czekanska et al., 2012). The process of osteogenesis
can also be investigated in in vitro osteogenic assays using bone-
derived cells originating from three different primary cell sources:
(1) fetal or neonatal calvarial cells (cells that form the upper portion
of the skull), (2) mesenchymal stromal cells, including bone-
marrow-derived multipotent mesenchymal stromal cells (BMSCs)
and periosteum-derived cells (PDCs) or (3) cells migrating from
trabecular bone explants (Czekanska et al., 2012). Some evidence
suggests that cells derived from OA bone have a different molecular
profile as compared to healthy controls. For instance, in a series of
experiments, Sanchez et al. demonstrated that the gene-expression
profile of OA sclerotic subchondral bone osteoblasts was
characterized by increased levels of MMP13, COL1A1 and
COL1A2, osteopontin, alkaline phosphatase, osteocalcin, and
vascular endothelial growth factor (Sanchez et al., 2008).
The cross-talk between chondrocytes and subchondral bone cells
seems essential to optimize the structure of the interface between the
hard mechanoresistant bone and the softer load-dissipating articular
cartilage. Molecular and cellular interactions between chondrocytes
and osteoblasts can be analyzed in a number of in vitro systems. For
example, Sanchez and co-authors used a co-culture model in which
chondrocytes were grown in inserts with a micro-pored membrane
upon a monolayer of osteoblasts isolated from OA or control
subchondral bone (Sanchez et al., 2005). In this system, the presence
of an insert allows the exchange of factors and molecules between
the cell layers and, afterwards, individual analysis of chondrocytes,
osteoblasts and of the conditioned medium can be performed. In
these co-cultures, osteoblasts isolated from sclerotic zones of
subchondral OA, but not those isolated from non-sclerotic regions,
could induce phenotypic changes in OA chondrocytes leading to
initiation of hypertrophic differentiation and subsequent matrix
mineralization (Sanchez et al., 2005). Therefore, these experiments
strongly support the key role of bone-cartilage cross-talk in driving
OA pathological processes.
Synovitis is increasingly recognized as an important contributor
to the development and progression of OA. Therefore, synovial
tissue explants, synovial cell cultures and synovium-cartilage co-
cultures have been employed as models to elucidate the role of the
synovium in OA and to identify potential mechanisms relevant to
the disease (Lee et al., 2013; van Buul et al., 2012). For instance,
Lee et al. demonstrated that co-cultures of normal synovium and
injured cartilage are associated with a protective effect of
synoviocytes by reducing the incidence of both focal cell loss and
chondrocyte cluster formation, two major hallmarks of OA.
In vivo models of OA
In vivo models aim to recapitulate OA-associated processes and
lesions in the whole animal. Reproducing features of OA in animal
systems is crucial to gain a better understanding of disease
mechanisms and to assess response to potential therapies, which is
a prerequisite for translating basic findings into therapies for
patients. Animal models of OA include naturally occurring OA in
REVIEW Disease Models & Mechanisms (2015) doi:10.1242/dmm.016881
D
is
ea
se
 M
od
el
s 
&
 M
ec
ha
ni
sm
s
(experimentally accelerated) aging, transgenic models, and
surgically or chemically induced OA (summarized in Tables 1 and
2). Unfortunately, none of these models can fully reproduce the
features and symptoms of human OA, owing to the complexity and
heterogeneity of the disease. Each model and species has its own
advantages and disadvantages (summarized in Table 1), and the
impact of preclinical research depends largely on the choice of the
most appropriate model of OA for the specific process that is under
investigation. For example, spontaneously occurring OA models
(which include aged animals or transgenic animals that develop OA
as an effect of a transgene) allow following the development of OA
from the early to the late stages, but are relatively costly and time
consuming and present with more variability in the disease
phenotype. By contrast, in surgical or chemical models of OA, the
disease can be rapidly induced and its manifestations are less
variable, but a limitation of these models is that they more reflect
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Table 1. Pros and cons of models of OA in different species 
Species Advantages Disadvantages Skeletal maturity References 
Mouse Low cost: easy management and handling 
Transgenic lines available 
Genome sequenced 
Small amount of drugs required in interventional 
studies 
Thin cartilage without clear zonal structure 
(compared with human cartilage) 
Small size, limiting technical procedures 
such as arthroscopy 
10 weeks Fang and Beier, 2014; 
Glasson et al., 2010 
 
Rat Low cost: easy management and handling 
Thick cartilage with complex zonal structure 
comparable to human cartilage 
Transgenic animals available in the near future 
Genome sequenced 
Availability of pain models 
More expensive than mice 
Small size, limiting technical procedures 
such as arthroscopy 
 
3 months Gerwin et al., 2010 
 
Guinea pig Easy management and handling 
Prone to spontaneous osteoarthritis 
More expensive than mice 
No transgenic lines available 
Sedentary lifestyle 
Small size, limiting technical procedures 
such as arthroscopy 
4-6 months Kraus et al., 2010 
Rabbit Easy management and handling 
Size allows easy tissue and fluid collection, and 
analysis of surgical strategies 
More expensive than mice 
No transgenic lines available 
Spontaneous healing of cartilage lesions 
8-9 months Laverty et al., 2010 
Dog Tractable and trainable 
Size allows easy tissue and fluid collection, and 
analysis of surgical strategies 
Some strains develop spontaneous OA 
High costs 
No transgenic lines available 
Genetic and phenotypic variability 
Public perception 
9-18 months Cook et al., 2010 
Goat/sheep Relatively easy management and handling 
Size allows easy tissue and fluid collection, and 
analysis of surgical strategies 
Thick cartilage and larger joints 
High costs 
No transgenic lines available 
Genetic and phenotypic variability 
Ruminant digestive system can interfere 
with oral drugs 
2 years Little et al., 2010 
Horse Size allows easy tissue and fluid collection, and 
analysis of surgical strategies 
Thick cartilage and larger joints 
Develops spontaneous OA 
High costs 
No transgenic lines available 
Genetic and phenotypic variability 
Public perception 
2 years McIlwraith et al., 2010 
 
 
Table 2. Commonly used OA models 
Type Species Examples Comments References 
Spontaneous Rodents, dogs, 
horses 
C57/Bl6, Balb/c and STR/ort strains in mice; 
treadmill running in rats; Dunkin-Hartley 
guinea pigs 
Clinically relevant, but high variability of  
the disease phenotype and incidence 
Mason et al., 2001; 
Stoop et al., 1999 
Chemically induced Rodents, 
rabbits, dogs, 
horses 
Monoiodoacetate, papain, collagenase, 
methylated bovine serum albumin, 
cytokines 
More difficult to translate to human setting; 
chondrocyte apoptosis can occur; local 
inflammation 
Guzman et al., 2003; 
Stanton et al., 2005; 
van der Kraan et al., 
1989 
Surgically induced Rodents, 
rabbits, goats, 
sheep, dogs, 
horses 
ACLT, MCLT, (p)MMx, MMT and patellectomy 
(kneecap removal), and combinations 
thereof 
More rapid disease onset and higher 
damage in the joint compared with 
human disease 
Hayami et al., 2006; 
Hayami et al., 2012; 
Kuroki et al., 2011; 
Little et al., 2010 
DMM in mice and rats Slow disease progression and mild 
cartilage damage; high clinical relevance 
Glasson et al., 2007 
Groove model in dogs No joint instability; one-time trauma Intema et al., 2008; 
Marijnissen et al., 
2002 
ACLT, anterior cruciate ligament transection; DMM, destabilization of the medial meniscus; MCLT, medial collateral ligament transection; MMT, medial 
meniscal tear; (p)MMx, partial medial menisectomy. D
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post-traumatic OA alterations rather than spontaneous changes
occurring in human OA. Small animals (mice, rats, rabbits and
guinea pigs) (Table 1) are most often used to investigate specific
disease mechanisms and for initial drug screenings for reasons of
cost-effectiveness, ease of handling and housing, and opportunity
for genetic manipulations. Large animal models (Table 1) show
more similarity to humans in terms of cartilage morphology, joint
anatomy and joint biomechanical function, and thus provide more
clinically relevant data. However, these models are relatively
expensive, present important ethical concerns and offer limited
possibility of genetic manipulations. Nevertheless, they are a crucial
preclinical system to validate potential therapeutic strategies. Most
animal models of OA are focused on the joint of the knee as this is
the main affected joint in human OA and its size is sufficiently large
to allow intra-articular manipulations even in small animals.
Small animal models
Mice are widely used as a research model because of the easy
management, low costs and the availability of genetically modified
lines. Originally, C57Bl/6 and BALB/c mice were widely employed
for the study of OA because aged animals of these strains develop
OA spontaneously (Stoop et al., 1999). However, more recently the
STR/ort mouse strain was discovered, which showed a more
pronounced form of OA (Mason et al., 2001); therefore, this strain
is now more often used in OA research, especially for drug
screening studies. The possibility to induce a wide range of genetic
modifications (for example, via the transgenic expression of a gene,
knock-out and knock-in strategies, inducible and tissue-specific gene
expression) makes mouse models an extremely useful tool for
replicating OA-associated genetic defects in the animal and
elucidating the molecular players that are involved in the
pathogenesis of the disease. For example, the crucial role of
catabolic enzymes such as MMP13 in OA was suggested by a study
in which the development of spontaneous articular cartilage damage
occurred after constitutive cartilage-specific overexpression of
MMP13 in mice (Neuhold et al., 2001). In some cases, mouse
genetics revealed complex interactions existing between a given
factor and OA. For instance, both cartilage-specific overexpression
of β-catenin (a crucial mediator of Wnt signalling) and of its
endogenous inhibitor led to OA development in mice, demonstrating
that a single pathway can contribute to OA through different
mechanisms (Zhu et al., 2008; Zhu et al., 2009).
Chemically and surgically induced models of OA in mice can be
obtained via different approaches. Intra-articular injections of
enzymes such as collagenase (van der Kraan et al., 1989) and papain
(van der Kraan et al., 1989) are commonly used to induce acute OA,
and are characterized by injury to the knee ligaments (leading to
severe joint instability and rapid cartilage breakdown) or by direct
enzymatic damage to the cartilage extracellular matrix (also
triggering further rapid cartilage breakdown), respectively (Fig. 3).
Inflammation-associated OA can be modelled by injections of
methylated bovine serum albumin (mBSA) (Stanton et al., 2005),
which triggers an acute inflammatory reaction in the joint. In this
model, different cytokines and infiltrating inflammatory cells have
a catabolic effect on the articular cartilage. Destructive surgical
models include partial medial meniscectomy (PMM), medial
collateral ligament transection (MCLT) and anterior cruciate
ligament transection (ACLT) (Clements et al., 2003; Hayami et al.,
2012). These models lead to severe OA pathology in mice and were
developed as translational models because meniscus injuries and
cruciate ligament injuries predispose to OA in humans. Finally, the
destabilization of the medial meniscus (DMM) surgical model
(Glasson et al., 2007) is a frequently used chronic model of OA in
mice, with a high clinical relevance (Fig. 3). The transection of the
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Acute (1-3 weeks) 
Collagenase model  Papain model DMM model 
Chronic (8-12 weeks)  
intra-articular injection 
destruction of ligaments and
tendons  
instability-driven OA 
indirect cartilage damage  
surgical transsection of ligament  
instability-driven OA 
indirect cartilage damage  
intra-articular injection 
proteoglycan degradation  
direct cartilage damage  
200 μm  200 μm  200 μm  
* 
AC 
AC 
M 
SB 
BM 
AC AC 
M 
M 
SB GP GP SB 
BM 
S 
AC 
AC 
BM 
Tibia Femur Tibia Femur Femur Tibia 
A B C 
Fig. 3. Examples of in vivo mouse models of induced OA of the knee, with typical histological appearance and main features. Each panel shows a
representative frontal hematoxylin–safranin-O-stained section of a mouse knee joint (medial condyle) with clear histopathological alterations: arrows indicate
cartilage fibrillation, triangles indicate loss of proteoglycans and asterisks indicate loss of cartilage. (A) Intra-articular injections of collagenase are used to
induce acute (within 1-3 weeks) damage to the ligaments and tendons of the knee. This will subsequently lead to secondary cartilage damage. (B) Intra-
articular injection of papain leads to acute direct cartilage damage, mainly characterized by an obvious loss of proteoglycans. (C) Destabilization of the medial
meniscus (DMM) is a more clinically relevant model in which dissection of the medial meniscus leads to destabilisation of the joint. After this surgical induction,
mice develop mild to severe histological features of OA within 8 weeks. Scale bars: 200 μm; original magnifications 10×. AC, articular cartilage; BM, bone
marrow; GP, growth plate; M, meniscus; S, synovium; SB, subchondral bone. D
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medial menisco-tibial ligament alters the mechanical stability of the
knee joint and induces cartilage damage; these alterations closely
resemble some of the changes that occur in progressive human OA
(Glasson et al., 2007). Mouse models are more extensively reviewed
elsewhere (Fang and Beier, 2014).
Mice are not an ideal system to model the alterations of the
biomechanical function of the joint that are associated with human
OA due to their small size as compared to humans. In addition, in
mice the cartilage of the knee has relatively few cell layers and a
reduced zonal tissue organization as compared to larger species,
which makes it difficult to mimic small lesions that slowly and
progressively extend through the different non-calcified layers of
cartilage, as reported in human OA (Glasson et al., 2010). Therefore,
these aspects can be better characterized in larger rodent and non-
rodent animal models.
Like mice, rats are relatively low-cost laboratory animals that are
easy to house and handle, but, unlike mice, naturally occurring OA
is extremely uncommon in rats and, although the technology to
generate transgenic and knockout lines is advancing in other fields
(Huang et al., 2011), transgenic rat models of OA are not yet
available. Nevertheless, rats possess a thicker cartilage with a
complex zonal structure, which makes partial and full cartilage
lesions possible to reproduce (Gerwin et al., 2010) via both chemical
[injection of iodoacetate (Guzman et al., 2003)] or surgical [medial
meniscal tear (MMT) or ACLT transections (Hayami et al., 2006)]
approaches. Rats are therefore an attractive animal model to test
cartilage repair strategies such as gene therapy, stem cell
transplantation, chondrocyte implantation and local growth factor
stimulation. Rat models have also been used for the assessment of
OA-related pain (Bove et al., 2006) and of novel OA pain therapies
(Ahmed et al., 2012; Cowart et al., 2012; Schuelert and McDougall,
2006).
Other small animal models of OA include rabbits (Laverty et al.,
2010) and guinea pigs (Kraus et al., 2010). The knee joint of the
rabbit shares some anatomical similarities with the human knee but,
because its biomechanical function is very different, rabbit models
are less suitable for functional studies. However, the larger size of
the joints as compared to mice has triggered interest in this species
as a source of cells for in vitro expansion and cell transfer studies.
Therefore, rabbit models of cartilage lesions are often used to test
cartilage repair strategies (Reyes et al., 2013). However, a
disadvantage is that young rabbits have a high potential for
spontaneous healing of cartilage and osteochondral lesions, thereby
limiting the translational value of the model. Finally, Hartley guinea
pigs are a frequently used model of OA because they develop OA
spontaneously and display progressive degenerative changes that
closely resemble the development of the disease in humans. The
guinea pig model has clear time-effectiveness advantages as
compared to large animal systems because the time of skeletal
maturation is much shorter in this species (Kraus et al., 2010). Bone
growth ceases by 4 months, although closure of the growth plates in
femur and tibia is only seen after 7 and 12 months, respectively.
However, early spontaneous changes in cartilage and bone, much
alike human OA, can be seen as early as 2 months after birth and
increase gradually until 18 months (Kraus et al., 2010).
Large animal models
A major advantage of using large animals is that they share more
similarities with humans in terms of macroscopic and microscopic
anatomy and, owing to their large size, topographical analysis of
joint cartilage by arthroscopy and serial aspiration of synovial fluid
for biomarker analysis are possible. In addition, these models are
also very useful for ex vivo/in vitro investigations because large
amounts of tissue samples and cells can be obtained. A disadvantage
is that histological analyses of large animal joints are more complex
because the whole joint cannot be captured on a single microscope
section.
The canine model is a valuable model for biomarker studies in
OA. Dogs are prone to develop naturally occurring OA with overuse
or age and receive similar treatments as humans (Cook et al., 2010;
Tirgari and Vaughan, 1975). Synovial fluid from OA-affected dogs
contains various MMPs, degradation products and cytokines that are
found in human samples, and these factors have been correlated to
cartilage breakdown and inflammation (Pelletier et al., 2005;
Pelletier et al., 2004). The most frequently used OA models in dogs
are the surgical ACLT (also known as Pond/Nuki model) (Kuroki et
al., 2011) and the groove (Intema et al., 2008) models. These models
show classical signs of OA, in particular progressive damage to the
articular cartilage, but the groove model is induced without joint
instability and is therefore expected to be more sensitive to treatment
because progression of the disease is milder and dependent on fewer
variables (Marijnissen et al., 2002).
Goats and sheep do not develop spontaneous OA (Little et al.,
2010), but surgically induced models are available and include
partial or total meniscectomy and the ACLT model, which, however,
only induces very mild cartilage damage (Little et al., 2010). These
large animals are particularly useful for the evaluation of surgical
interventions. In addition, the anatomy and in particular the
thickness of their cartilage more closely resemble those of human
cartilage as compared to rodents. A disadvantage of these models is
that ruminants have a peculiar digestive system that can alter the
bioavailability of drugs and, thus, they are not very suitable for
testing orally administered therapies.
Measures of disease outcome in animal research
The assessment of joint damage, in particular of cartilage loss, is an
essential aspect in animal research and preclinical drug testing.
Pioneering work to define criteria for the histopathological
assessment of OA was performed by Collins (Collins, 1939), who
established a grading system (Grades I-IV) based on the degree of
fibrillation of articular cartilage, defined as fraying of its smooth
surface. In 1971, Mankin (Mankin, 1971) developed a microscopic
histologic histochemical grading system (HHGS; 14-point scoring
system) based on the evaluation of a range of cellular changes,
extracellular matrix alterations as revealed by staining with Safranin
O, and structural changes. Although these scoring systems are still
in use, they have many limitations, particularly concerning their
potential for the assessment of early OA. This guided the efforts
from both academic and industrial OA researchers for developing a
standard histological grading system that could advance data
interpretation across distinct model systems and provide better
criteria for evaluating the outcome of OA treatments. Therefore, the
Osteoarthritis Research Society International (OARSI)
histopathology initiative (Berenbaum, 2010) defined a standardized
scoring system for the most important small and large animal
models in which joint degeneration is assessed based on specific
evaluation of both depth and extent (surface) of lesions. Ideally,
macroscopic and microscopic evaluation of OA features should be
extended to non-cartilaginous structures given their important
contribution to the disease process. In this regard, the OARSI
histopathology initiative filled the gaps of previous scoring systems
and provided additional scoring parameters to assess alterations in
the synovium, subchondral bone, menisci, tendons and ligaments
(Cook et al., 2010; Gerwin et al., 2010; Glasson et al., 2010; Kraus
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et al., 2010; Laverty et al., 2010; Little et al., 2010; McIlwraith et
al., 2010). As compared to cartilage scoring systems, analysis of the
other tissues of the joint might still suffer from lack of standardized,
validated and comprehensive methodologies. Because these
methodologies are still semi-quantitative and partially affected by
inter- and intra-observer variability, they are often supported by
histomorphometric analyses, which can more reliably quantify
cartilage thickness, proteoglycan content, subchondral bone size and
synovium width (Pastoureau et al., 2010).
As an alternative to histopathological analyses, which are a time-
consuming method, non-invasive imaging techniques such as
magnetic resonance imaging (MRI) and micro computed
tomography (microCT) are becoming popular in OA animal studies.
Non-invasive in vivo imaging can be used for longitudinal follow-
up in the same animal to monitor the disease progression and the
response to treatments in drug trials. Standard clinical MRI (1.5 and
3T) is being used in large animal models (dogs, goats, sheep and
horses) to assess OA-associated alterations in subchondral bone
marrow, synovial fluid volume and soft tissue structures such as the
articular cartilage and the synovium (Galindo-Zamora et al., 2013;
Ley et al., 2013). Rodents and rabbits are too small to undergo
standard in vivo MRI but, recently, high-resolution micro-MRI
(>7T) has been developed for these species to monitor cartilage
lesions in surgically induced models of OA (Batiste et al., 2004;
Goebel et al., 2010). This technique needs further optimization and
is still challenging because it requires the use of specific magnetic
coils. Micro-CT is also available but can be used only for high-
resolution imaging of bone architecture alterations. Indeed, owing
to its low soft-tissue contrast, direct imaging of the cartilage is not
feasible with this approach. However, the combination of contrast
agents, such as ioxaglate and hexabrix, which allow the visualization
of the cartilage, with nano-CT might represent an alternative to
conventional microscopy (Kerckhofs et al., 2013).
Biomarker analysis is another non-invasive approach to assess
cartilage or bone turnover, as well as synovitis in OA. Serum and
urine samples contain biomarkers such as aggrecan and collagen
neoepitopes that can be considered as breakdown products of the
cartilage extracellular matrix and that could help predict the efficacy
of new drugs in animal models (Kraus et al., 2011; Rousseau et al.,
2010). Unfortunately, these biomarkers are highly diluted in the
blood plasma and in the urine, and exhibit large inter-individual
variations, thus requiring highly sensitive techniques.
Pain-related outcomes are beyond the scope of this article but
mechanisms of pain in OA, including methods for assessing pain in
animal models, have been recently reviewed elsewhere (Malfait et
al., 2013).
Concluding remarks and future directions
OA research offers a range of valid approaches that are currently
contributing to advancing our understanding of the disease. The
different in vivo and in vitro models of disease discussed in this
Review have contributed in different ways to bring insights into the
disease process. Some of these discoveries, including the essential
role of growth factors, the identification of key tissue-destructive
enzymes and, more lately, the recognition that inflammation is also
an important contributor to OA, have suggested potential novel
therapeutic targets for OA and support the need to develop new and
effective strategies. However, in a translational view, taking basic
knowledge from bench to bedside is still a big challenge. One main
problem is related to the lack of a ‘holistic’ view of the disease: the
focus of OA research should be shifted from an approach solely
considering the articular cartilage to a system biology approach,
based on the study of the different components of the joint and of
their interactions, in order to better understand mechanisms of whole
joint failure in OA. In addition, a better definition of disease stages
is highly needed. It is becoming clear that early and established OA
likely represent heterogeneous diseases, and efforts are ongoing to
define classification criteria to differentiate these stages. This would
guide more appropriate and timely therapeutic interventions, which
could allow more efficient interference with disease progression, as
seen in other joint diseases such as rheumatoid arthritis (Luyten et
al., 2012).
Finally, one of the biggest challenges in OA is related to
heterogeneity of the clinical presentations of the disease. Multiple
subsets of patients can exist, with very different molecular, clinical and
epidemiological profiles, which makes phenotyping of OA patients
particularly challenging. In cohort studies and clinical trials, OA is still
commonly defined and classified based on conventional radiographs.
Such an approach does not consider and integrate emerging important
information about disease mechanisms that is becoming available from
the application of novel ‘omics’ technologies and advanced
bioinformatic approaches. Other important features that should be
taken into account in the classification of patient subsets include the
type of OA-associated pain (for example, pain directly attributable to
the joint tissue, pain associated with the phenomena of sensitization
such as neuropathic pain, psychologically mediated pain), the type of
bone reaction [OA hypertrophic versus atrophic bone reaction
(Castaño Betancourt et al., 2013)], the identification of genetic
susceptibility factors, and the presence or absence of a main causative
mechanism (metabolic-driven OA, inflammation-driven OA,
mechanically driven OA). Redefining the number of parameters and
classification criteria that are used for patient phenotyping would likely
help identify patients at a high or low risk to develop severe OA,
predict responders and non-responders to a specific intervention, and
would hopefully guide the development of personalized treatments,
with a high rewarding impact on both patient life and society.
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